Rozman C, Montserrat Costa E, Morey M, Aranalde J M, Feliú E, Grañena A, Hernández Nieto L, Nomdedeu B
Med Clin (Barc). 1979 Apr 10;72(7):265-71.
The prognosis of patients with chronic lymphocytic leukemia is very difficult to evaluate. The classification system by stages, which at the present time is the most simple and useful method for the prognosis of this disease, recognizes five degrees of involvement: stage 0 (medullary and peripheral lymphocytosis); stage I (lymphocytosis + enlarged lymph nodes); stage II (lymphocyosis + hepato-and/or splenomegaly); stage III (lymphocytosis + anemia), and stage IV (lymphocytosis + thrombocytopenia). In the present report 95 controlled patients at the Farreras Valentí School of Hematology are analyzed using the classification by stages; there were 19 cases in stage 0; 16 in stage I; 30 in stage II; 21 in stage III, and 9 in stage IV. The mean survival rate in the global series was 63 months and the average 90.9 months. As in other series, it was observed that patients in stages 0 and I have a much better prognosis than those in stages III and IV. Stage II occupies an intermediate position in relation to prognosis, since the actuarial survival figure for this stage can practically be superimposed on that of the global series. The classification of chronic lymphocytic leukemia by stages permits the specification of the therapeutic indications for this condition; it also encourages the search for new modalities of treatment for stages with poor prognosis, since in these cases chronic lymphocytic leukemia behaves in the manner of an acute or subacute hemopathy.
慢性淋巴细胞白血病患者的预后很难评估。目前,分期分类系统是预测该疾病预后最简单且最有用的方法,它识别出五个受累程度:0期(骨髓和外周淋巴细胞增多);I期(淋巴细胞增多+淋巴结肿大);II期(淋巴细胞增多+肝脾肿大);III期(淋巴细胞增多+贫血),以及IV期(淋巴细胞增多+血小板减少)。在本报告中,对法雷拉斯·瓦伦蒂血液学学校的95例对照患者采用分期分类进行分析;0期有19例;I期有16例;II期有30例;III期有21例,IV期有9例。整个系列的平均生存率为63个月,平均生存期为90.9个月。与其他系列一样,观察到0期和I期患者的预后比III期和IV期患者好得多。II期在预后方面处于中间位置,因为该期的精算生存数据实际上与整个系列的数据重叠。慢性淋巴细胞白血病的分期分类有助于明确该疾病的治疗指征;它还促使人们寻找针对预后不良阶段的新治疗方式,因为在这些情况下,慢性淋巴细胞白血病表现为急性或亚急性血液病。